|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0038250,
umls-concept:C0054961,
umls-concept:C0175630,
umls-concept:C0278678,
umls-concept:C0332293,
umls-concept:C0441889,
umls-concept:C1268567,
umls-concept:C1274040,
umls-concept:C1332710,
umls-concept:C1334306,
umls-concept:C2757011
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-3-30
|
|
pubmed:abstractText |
Predicting the efficacy of antiangiogenic therapy would be of clinical value in patients (pts) with metastatic renal cell carcinoma (mRCC). We tested the hypothesis that circulating endothelial cell (CEC), bone marrow-derived CD45(dim)CD34(+)VEGFR2(+) progenitor cell or plasma angiogenic factor levels are associated with clinical outcome in mRCC pts undergoing treatment with tyrosine kinase inhibitors (TKI).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-10406801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-11689883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-12538485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-14745444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-15466206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-15534359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-15711737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-15723071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-16341007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-16611400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-16837971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-16990548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17215529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17215530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17222792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17575055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17605814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-17693656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-18187653,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-18506173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-18650835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-18662694,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-19417649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-19451442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-19605404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21386843-20010948
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
29
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1144-50
|
|
pubmed:dateRevised |
2011-7-28
|
|
pubmed:meshHeading |
pubmed-meshheading:21386843-Adult,
pubmed-meshheading:21386843-Aged,
pubmed-meshheading:21386843-Aged, 80 and over,
pubmed-meshheading:21386843-Antigens, CD34,
pubmed-meshheading:21386843-Antigens, CD45,
pubmed-meshheading:21386843-Carcinoma, Renal Cell,
pubmed-meshheading:21386843-Female,
pubmed-meshheading:21386843-Hematopoietic Stem Cells,
pubmed-meshheading:21386843-Humans,
pubmed-meshheading:21386843-Kidney Neoplasms,
pubmed-meshheading:21386843-Male,
pubmed-meshheading:21386843-Middle Aged,
pubmed-meshheading:21386843-Protein Kinase Inhibitors,
pubmed-meshheading:21386843-Protein-Tyrosine Kinases,
pubmed-meshheading:21386843-Treatment Outcome,
pubmed-meshheading:21386843-Vascular Endothelial Growth Factor A,
pubmed-meshheading:21386843-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
|
|
pubmed:affiliation |
Translational Research Laboratory, Institut de Cancérologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France. farace@igr.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
